Poisoning – Pipeline Review, Q3 2011
Poisoning - Pipeline Review, Q3 2011
Reference Code: GMDHC1188IDB
Publication Date: July 2011
Poisoning – Pipeline Review, Q3 2011 GMDHC1188IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
Page(1)
Poisoning – Pipeline Review, Q3 2011
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Poisoning Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Poisoning 8
Poisoning Therapeutics under Development by Companies 10
Poisoning Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Poisoning Therapeutics - Products under Development by Companies 16
Poisoning Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Poisoning Therapeutics Development 18
Cangene Corporation 18
PharmAthene, Inc. 18
Mondobiotech Holding AG 19
Aton Pharma, Inc. 19
MicroDose Therapeutx, Inc. 20
Poisoning - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Protexia - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Atropine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Atropine Sulfate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Ricin Immune Globulin - Drug Profile 30
Product Description 30
Mechanism of Action 30
Poisoning – Pipeline Review, Q3 2011 GMDHC1188IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Poisoning – Pipeline Review, Q3 2011
R&D Progress 30
Diazepam - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Clonidine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Fructose-1,6-Diphosphate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Carboplatin + Sodium Thiosulfate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Buprenorphine + Naloxone - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ATON 004 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ATON 009 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Penicillamine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DasKloster 0210-01 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VINS Polyvalent Antivenom - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Poisoning Therapeutics – Drug Profile Updates 41
Poisoning - Featured News 42
Jun 07, 2011: MicroDose Therapeutx Announces Successful Completion Of Phase I Pilot Study Of Inhaled Atropine As Antidote To
Combat Effects Of Nerve Agent Poisoning 42
Jan 04, 2011: Protalix To Present PRX-105 Data At BARDA Industry Day 43
Nov 22, 2010: Soligenix Receives US Patent For RiVax Vaccine Against Ricin Toxin 43
Nov 02, 2010: Soligenix Completes Enrollment And Preliminary Safety Results Of Phase IB Clinical Trial For RiVax 44
Poisoning – Pipeline Review, Q3 2011 GMDHC1188IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Poisoning – Pipeline Review, Q3 2011
Sep 14, 2010: United States FDA grants mondoBIOTECH’s Medicinal Product Candidate DasKloster0210 the Orphan Drug Designation
For The Treatment Of Chron